Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Topical Isotretinoin (TMB-001) Treatment for 12 Weeks Did Not Result in Clinically Relevant Laboratory Abnormalities in Participants with Congenital Ichthyosis in the Phase 2b CONTROL Study.
Marathe K, Teng JMC, Guenthner S, Bunick CG, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn AM, Raiz J, Murrell DF. Marathe K, et al. Among authors: mendelsohn am. Dermatol Ther (Heidelb). 2023 Jun;13(6):1255-1264. doi: 10.1007/s13555-023-00923-1. Epub 2023 May 11. Dermatol Ther (Heidelb). 2023. PMID: 37170057 Free PMC article.
Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis.
Murrell DF, Teng JMC, Guenthner S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn AM, Raiz J, Bunick CG. Murrell DF, et al. Among authors: mendelsohn am. Clin Exp Dermatol. 2023 Jun 5;48(6):623-630. doi: 10.1093/ced/llad033. Clin Exp Dermatol. 2023. PMID: 36794376 Clinical Trial.
Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study.
Bunick CG, Teng JMC, Guenthner S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn AM, Raiz J, Murrell DF. Bunick CG, et al. Among authors: mendelsohn am. Clin Exp Dermatol. 2023 Jul 7;48(7):765-769. doi: 10.1093/ced/llad105. Clin Exp Dermatol. 2023. PMID: 36928932 Clinical Trial.
The CONTROL study: A randomized, double-blind vehicle-controlled phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosis.
Teng JMC, Bunick CG, Guenthner S, Murrell DF, Marathe K, Kempers S, Eads K, Mendelsohn AM, Raiz J, Tavakkol A, Castelo-Soccio L. Teng JMC, et al. Among authors: mendelsohn am. J Am Acad Dermatol. 2022 Dec;87(6):1455-1458. doi: 10.1016/j.jaad.2022.07.028. Epub 2022 Jul 21. J Am Acad Dermatol. 2022. PMID: 35872261 Free article. Clinical Trial. No abstract available.
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.
Fernandez AP, Dauden E, Gerdes S, Lebwohl MG, Menter MA, Leonardi CL, Gooderham M, Gebauer K, Tada Y, Lacour JP, Bianchi L, Egeberg A, Pau-Charles I, Mendelsohn AM, Rozzo SJ, Mehta NN. Fernandez AP, et al. Among authors: mendelsohn am. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1774-1783. doi: 10.1111/jdv.18167. Epub 2022 Jun 25. J Eur Acad Dermatol Venereol. 2022. PMID: 35460287 Free PMC article. Clinical Trial.
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study.
Mease PJ, Chohan S, Fructuoso FJG, Luggen ME, Rahman P, Raychaudhuri SP, Chou RC, Mendelsohn AM, Rozzo SJ, Gottlieb A. Mease PJ, et al. Among authors: mendelsohn am. Ann Rheum Dis. 2021 Sep;80(9):1147-1157. doi: 10.1136/annrheumdis-2020-219014. Epub 2021 May 13. Ann Rheum Dis. 2021. PMID: 33985942 Free PMC article. Clinical Trial.
Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).
Igarashi A, Nakagawa H, Morita A, Okubo Y, Sano S, Imafuku S, Tada Y, Honma M, Mendelsohn AM, Kawamura M, Ohtsuki M. Igarashi A, et al. Among authors: mendelsohn am. J Dermatol. 2021 Jun;48(6):853-863. doi: 10.1111/1346-8138.15789. Epub 2021 Feb 25. J Dermatol. 2021. PMID: 33630387 Free PMC article. Clinical Trial.
57 results